Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 6.2% - What's Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) fell 6.2% on Monday . The stock traded as low as $4.98 and last traded at $4.95. 4,679,937 shares traded hands during trading, a decline of 71% from the average session volume of 15,996,274 shares. The stock had previously closed at $5.27.

Analyst Ratings Changes

Several research firms recently weighed in on RXRX. Morgan Stanley began coverage on Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 target price on the stock. Needham & Company LLC reiterated a "buy" rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $7.00.

Recursion Pharmaceuticals Trading Up 1.7%

The business has a fifty day moving average price of $4.82 and a 200 day moving average price of $6.09. The company has a market capitalization of $2.31 billion, a PE ratio of -3.18 and a beta of 0.91. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.11 and a current ratio of 4.11.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). The firm had revenue of $14.75 million during the quarter, compared to analysts' expectations of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The business's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.39) earnings per share. Analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently modified their holdings of RXRX. AlphaQuest LLC purchased a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at about $36,000. GAMMA Investing LLC raised its holdings in shares of Recursion Pharmaceuticals by 39.0% during the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock valued at $38,000 after buying an additional 2,026 shares during the period. Farther Finance Advisors LLC raised its holdings in shares of Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after buying an additional 1,353 shares during the period. NewEdge Advisors LLC raised its holdings in shares of Recursion Pharmaceuticals by 43.7% during the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after buying an additional 2,387 shares during the period. Finally, GF Fund Management CO. LTD. purchased a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at about $54,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.